Korro Bio, Inc. announced that Ram Aiyar, Ph.D., MBA, Chief Executive Officer, will present at the 2022 Jefferies Healthcare Conference, being held in New York, NY, on Thursday, June 9, 2022, at 10:30 a.m. EDT.
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced that Ram Aiyar, Ph.D., MBA, Chief Executive Officer, will present at the 2022 Jefferies Healthcare Conference, being held in New York, NY, on Thursday, June 9, 2022, at 10:30 a.m. EDT.
About Korro Bio, Inc.
Korro is an RNA editing company focused on discovery and development of a new class of precision genetic medicines. Korro’s proprietary and modular platform, OPERATM, combines data-driven design with off-the-shelf chemistry and delivery to achieve highly selective RNA editing. This unique technology enables the functional benefits of gene therapy with a transient, repeated-administration regimen that permits pharmacologic titration of therapeutic efficacy and safety, in a cost-effective drug product. As a result, Korro’s portfolio of innovative RNA therapies have the potential to propel genetic medicine beyond rare genetic diseases into larger patient populations with common diseases. Korro is located in Cambridge, Mass. For more information, visit korrobio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005971/en/
Contacts
Investors
Vineet Agarwal
vagarwal@korrobio.com
Media
Chris Railey
Ten Bridge Communications
chris@tenbridgecommunications.com
Source: Korro Bio, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20220606005971/en
